🔗 Share this article

The prestigious award in medical science has been granted for revolutionary discoveries that clarify how the body's defense network targets harmful pathogens while protecting the body's own cells.

Three esteemed scientists—Japan's Shimon Sakaguchi and American scientists Mary Brunkow and Dr. Ramsdell—received this honor.

The research uncovered unique "sentinels" within the immune system that remove rogue immune cells capable of attacking the body.

These discoveries are now paving the way for innovative treatments for autoimmune diseases and cancer.

The winners will share a monetary award valued at 11m Swedish kronor.

Crucial Findings

"The work has been essential for comprehending how the body's defenses functions and the reason we don't all develop severe autoimmune diseases," commented the head of the Nobel Committee.

The team's research address a core question: In what way does the defense system defend us from numerous invaders while keeping our healthy cells unharmed?

Our body's protection system employs immune cells that search for signs of disease, including viruses and bacteria it has never encountered.

These defenders utilize detectors—called recognition units—that are generated by chance in a vast number of variations.

That provides the defense network the capacity to combat a broad range of threats, but the unpredictability of the process unavoidably produces white blood cells that can target the host.

Protectors of the Body

Scientists previously knew that some of these harmful white blood cells were destroyed in the thymus—the site where immune cells mature.

The latest Nobel Prize recognizes the discovery of T-reg cells—described as the immune system's "security guards"—which patrol the system to neutralize other immune cells that attack the body's own tissues.

We know that this process fails in autoimmune diseases such as juvenile diabetes, MS, and RA.

A Nobel panel stated, "These findings have established a novel area of research and spurred the creation of innovative therapies, for example for tumors and immune disorders."

Regarding malignancies, T-regs prevent the system from attacking the tumor, so studies are focused on reducing their numbers.

For autoimmune diseases, trials are exploring boosting T-reg cells so the body is no longer being harmed. A comparable approach could also be useful in minimizing the risks of transplanted organ rejection.

Pioneering Studies

Prof Sakaguchi, from Osaka University, conducted experiments on mice that had their thymus removed, leading to self-attack conditions.

He showed that introducing defense cells from healthy mice could prevent the disease—implying there was a mechanism for preventing immune cells from harming the host.

Dr. Brunkow, affiliated with the Institute for Systems Biology in a US city, and Fred Ramsdell, now at a biotech firm in San Francisco, were investigating an inherited immune disorder in rodents and people that led to the discovery of a gene critical for how T-regs function.

"Their pioneering research has uncovered how the body's defenses is kept in check by regulatory T cells, stopping it from mistakenly targeting the body's own tissues," said a leading physiology specialist.

"This research is a striking example of how basic physiological study can have far-reaching implications for public health."